Life's essential 8 and mortality in US adults with metabolic dysfunction-associated steatotic liver disease

被引:0
|
作者
Zhang, Yingying [1 ]
Wang, Pingping [2 ]
Tu, Fan [1 ]
Kang, Hao [3 ]
Fu, Chengfeng [4 ]
机构
[1] Jiangnan Univ, Affiliated Wuxi Hosp 5, Med Lab Ctr, 1215 Guangrui Rd, Wuxi 214005, Jiangsu, Peoples R China
[2] Yangzhou Univ, Taizhou Peoples Hosp 2, Dept Clin Lab, Taizhou, Jiangsu, Peoples R China
[3] Jiangnan Univ, Affiliated Wuxi Hosp 5, Res Ctr Clin Med Sci, Wuxi, Jiangsu, Peoples R China
[4] Second Peoples Hosp Banan Dist, Resp & Crit Care Med, 18 Huaxi New Village,Huaxi St, Chongqing 400054, Peoples R China
关键词
MASLD; Life's essential 8; All-cause mortality; CVD mortality; National health and nutrition examination survey; AMERICAN HEART ASSOCIATIONS; CARDIOVASCULAR HEALTH; METAANALYSIS; OUTCOMES; METRICS; NHANES; RISK;
D O I
10.1186/s12889-024-20919-6
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to increased all-cause mortality due to metabolic dysfunctions like obesity, diabetes, and cardiovascular diseases. This study examines the association between Life's Essential 8 (LE8) scores and both all-cause and cardiovascular disease (CVD) mortality in MASLD participants. Methods Data from 5,916 MASLD participants in the NHANES (2005-2018) were analyzed. Associations between LE8 scores and all-cause and CVD mortality were assessed using Cox proportional hazards models, with follow-up until December 31, 2019. Dose-response relationships and survival differences were evaluated using Kaplan-Meier survival curves and Restricted Cubic Spline models. Results Over a median follow-up of 7.6 years, moderate and high LE8 scores were associated with 33% (HR: 0.67; 95% CI: 0.56-0.79) and 47% (HR: 0.53; 95% CI: 0.33-0.84) lower risk of all-cause mortality, respectively, compared to low scores. For CVD mortality, the adjusted HRs were 0.56 (95% CI: 0.41-0.78) and 0.35 (95% CI: 0.12-1.0). Higher LE8 scores were significantly associated with reduced cumulative incidence of all-cause and CVD mortality (log-rank P < 0.001). A 10-point increase in health behavior scores, particularly in diet, physical activity, and nicotine exposure, was linked to an 11% reduction in all-cause mortality risk and an 11% reduction in CVD mortality risk. Among health factors, only blood glucose showed a significant association with CVD mortality. Conclusion Higher LE8 scores in MASLD patients are associated with lower mortality risk, suggesting the potential value of promoting cardiovascular health in this population. Further research is needed to confirm these associations.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Iron, Oxidative Stress, and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Gensluckner, Sophie
    Wernly, Bernhard
    Datz, Christian
    Aigner, Elmar
    ANTIOXIDANTS, 2024, 13 (02)
  • [42] Metabolic dysfunction-associated steatotic liver disease : the tree that hides the forest ?
    Henin, G.
    Baldin, P.
    Frans, C.
    Havelange, V.
    Delire, B.
    Yombi, J. C.
    Lanthier, N.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2024, 87 (02) : 344 - 345
  • [43] Chemoprevention of hepatocellular carcinoma associated with metabolic dysfunction-associated steatotic liver disease: an updated review
    Dickinson, Averie
    Dinani, Amreen
    Wegermann, Kara
    HEPATOMA RESEARCH, 2024, 10
  • [44] A healthy lifestyle is prospectively associated with lower onset of metabolic dysfunction-associated steatotic liver disease
    Grinshpan, Laura S.
    Haim, Yaara Even
    Ivancovsky-Wajcman, Dana
    Fliss-Isakov, Naomi
    Nov, Yuval
    Webb, Muriel
    Shibolet, Oren
    Kariv, Revital
    Zelber-Sagi, Shira
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (11)
  • [45] Predictors of Atherosclerotic Cardiovascular Disease Events in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease
    Kawanaka, Miwa
    Nishino, Ken
    Kawada, Mayuko
    Ishii, Katsunori
    Tanikawa, Tomohiro
    Urata, Noriiyo
    Suehiro, Mitsuhiko
    Haruma, Ken
    Kawamoto, Hirofumi
    INTERNAL MEDICINE, 2024,
  • [46] A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease
    Ramos, Maria Jimenez
    Kendall, Timothy J.
    Drozdov, Ignat
    Fallowfield, Jonathan A.
    ANNALS OF HEPATOLOGY, 2024, 29 (02)
  • [47] New insights into metabolic dysfunction-associated steatotic liver disease and oxidative balance score
    Peng, Lei
    Li, Lurong
    Liu, Jiahao
    Li, Yuanyuan
    FRONTIERS IN NUTRITION, 2024, 10
  • [48] Metabolic Dysfunction-Associated Steatotic Liver Disease and Polycystic Ovary Syndrome: A Complex Interplay
    Arvanitakis, Konstantinos
    Chatzikalil, Elena
    Kalopitas, Georgios
    Patoulias, Dimitrios
    Popovic, Djordje S.
    Metallidis, Symeon
    Kotsa, Kalliopi
    Germanidis, Georgios
    Koufakis, Theocharis
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (14)
  • [49] Celiac Disease, Gluten-Free Diet and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Cazac, Georgiana-Diana
    Mihai, Bogdan-Mircea
    Stefanescu, Gabriela
    Gilca-Blanariu, Georgiana-Emmanuela
    Mihai, Catalina
    Grigorescu, Elena-Daniela
    Onofriescu, Alina
    Lacatusu, Cristina-Mihaela
    NUTRIENTS, 2024, 16 (13)
  • [50] Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis
    Tincopa, Monica A.
    Loomba, Rohit
    SEMINARS IN LIVER DISEASE, 2024, 44 (03) : 287 - 299